Addex Therapeutics Ltd (ADXN) - Cash Flow Conversion Efficiency

Latest as of March 2026: -0.233x

Based on the latest financial reports, Addex Therapeutics Ltd (ADXN) has a cash flow conversion efficiency ratio of -0.233x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CHF-765.84K ≈ $-968.23K USD) by net assets (CHF3.29 Million ≈ $4.16 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is Addex Therapeutics Ltd worth for the company's overall valuation and market capitalisation.

Addex Therapeutics Ltd - Cash Flow Conversion Efficiency Trend (2006–2025)

This chart illustrates how Addex Therapeutics Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Addex Therapeutics Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Addex Therapeutics Ltd ranked by their cash flow conversion efficiency. Explore ADXN cash flow quality index to measure how well operating cash flow supports reported net income.

Company Cash Flow Conversion Efficiency
TwentyFour Select Monthly Income Fund Ltd
LSE:SMIF
0.045x
Cemtrex Inc
NASDAQ:CETX
0.013x
Intelligent Group Limited Ordinary Shares
NASDAQ:INTJ
-0.001x
Trucknet Enterprise Ltd
TA:TRAN
N/A
Groupe Airwell Société anonyme
PA:ALAIR
-0.126x
Aldrich Resources Bhd
KLSE:0079
-0.587x
G Capital Public Company Limited
BK:GCAP
-0.071x
Keyang Electric Machinery Co Ltd
KO:012205
-0.186x

Annual Cash Flow Conversion Efficiency for Addex Therapeutics Ltd (2006–2025)

The table below shows the annual cash flow conversion efficiency of Addex Therapeutics Ltd from 2006 to 2025. View Addex Therapeutics Ltd stock quote for real-time trading data and today's change.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 CHF4.76 Million
≈ $6.02 Million
CHF-2.17 Million
≈ $-2.75 Million
-0.456x +17.85%
2024-12-31 CHF9.67 Million
≈ $12.23 Million
CHF-5.37 Million
≈ $-6.79 Million
-0.556x +92.04%
2023-12-31 CHF1.15 Million
≈ $1.45 Million
CHF-7.99 Million
≈ $-10.10 Million
-6.977x -108.55%
2022-12-31 CHF4.91 Million
≈ $6.21 Million
CHF-16.44 Million
≈ $-20.78 Million
-3.346x -285.22%
2021-12-31 CHF16.93 Million
≈ $21.41 Million
CHF-14.71 Million
≈ $-18.59 Million
-0.869x -4.18%
2020-12-31 CHF14.61 Million
≈ $18.47 Million
CHF-12.18 Million
≈ $-15.40 Million
-0.834x -124.41%
2019-12-31 CHF25.52 Million
≈ $32.27 Million
CHF-9.48 Million
≈ $-11.99 Million
-0.372x -932.20%
2018-12-31 CHF39.24 Million
≈ $49.61 Million
CHF1.75 Million
≈ $2.21 Million
0.045x +102.81%
2017-12-31 CHF1.34 Million
≈ $1.70 Million
CHF-2.13 Million
≈ $-2.70 Million
-1.590x +87.10%
2016-12-31 CHF218.59K
≈ $276.36K
CHF-2.69 Million
≈ $-3.41 Million
-12.326x -680.44%
2015-12-31 CHF1.66 Million
≈ $2.10 Million
CHF-2.63 Million
≈ $-3.32 Million
-1.579x -105.86%
2014-12-31 CHF2.35 Million
≈ $2.97 Million
CHF-1.80 Million
≈ $-2.28 Million
-0.767x +85.28%
2013-12-31 CHF3.03 Million
≈ $3.83 Million
CHF-15.78 Million
≈ $-19.95 Million
-5.214x -188.38%
2012-12-31 CHF16.29 Million
≈ $20.60 Million
CHF-29.45 Million
≈ $-37.24 Million
-1.808x -130.40%
2011-12-31 CHF33.84 Million
≈ $42.78 Million
CHF-26.55 Million
≈ $-33.57 Million
-0.785x -61.27%
2010-12-31 CHF64.41 Million
≈ $81.44 Million
CHF-31.34 Million
≈ $-39.62 Million
-0.487x +4.14%
2009-12-31 CHF77.58 Million
≈ $98.08 Million
CHF-39.38 Million
≈ $-49.78 Million
-0.508x -239.45%
2008-12-31 CHF118.99 Million
≈ $150.44 Million
CHF-17.79 Million
≈ $-22.49 Million
-0.150x +36.53%
2007-12-31 CHF140.11 Million
≈ $177.13 Million
CHF-33.00 Million
≈ $-41.73 Million
-0.236x +49.08%
2006-12-31 CHF42.28 Million
≈ $53.45 Million
CHF-19.56 Million
≈ $-24.73 Million
-0.463x --

About Addex Therapeutics Ltd

SW:ADXN Switzerland Biotechnology
Market Cap
$4.26 Million
CHF3.37 Million CHF
Market Cap Rank
#29147 Global
#213 in Switzerland
Share Price
CHF0.02
Change (1 day)
-0.89%
52-Week Range
CHF0.02 - CHF0.07
All Time High
CHF3.90
About

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson's disease levodopa-in… Read more